Evidence map›Paper›PMID 25761460›Full record

ArticleClinical and vaccine immunology : CVI2015

Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.

Jordan K Kyongo, Tania Crucitti, Joris Menten, Liselotte Hardy, Piet Cools, Johan Michiels, Sinead Delany-Moretlwe, Mary Mwaura, Gilles Ndayisaba, Sarah Joseph and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Bacterial Load ofMicroorganisms · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. mBio · 2024
    Article
  13. Article
  14. Article
  15. Second trimester vaginalFrontiers in global women's health · 2024
    Article
  16. Article
  17. Article
  18. Interactions between microbiota and cervical epithelial, immune, and mucus barrier.Frontiers in cellular and infection microbiology · 2023
    Review
  19. Article
  20. Advances in integrative African genomics.Trends in genetics : TIG · 2022
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 5 countries.

Jordan K KyongoVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Tania CrucittiHIV/STI Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Joris MentenClinical Trials Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Liselotte HardyHIV/STI Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium Unit of Epidemiology and Control of HIV/STD, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Piet CoolsFaculty of Medicine and Health Sciences, Department of Microbiology, Immunology, and Clinical Chemistry, Ghent University, Ghent, Belgium.
Johan MichielsVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Sinead Delany-MoretlweWits Reproductive Health and HIV Institute, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Mary MwauraInternational Center for Reproductive Health, Mombasa, Kenya.
Gilles NdayisabaRinda Ubuzima, Kigali, Rwanda.
Sarah JosephMRC Clinical Trials Unit at University College London, London, United Kingdom.
Raina FichorovaLaboratory of Genital Tract Biology, Department of Obstetrics, Gynaecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Janneke van de WijgertInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Guido VanhamVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium Faculty of Pharmaceutical, Veterinary, and Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Kevin K AriënVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Vicky JespersUnit of Epidemiology and Control of HIV/STD, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium vjespers@itg.be.
Instituut voor Tropische Geneeskunde · BEBrigham and Women's Hospital · USInternational Centre for Reproductive Health Kenya · KEMRC Clinical Trials Unit at UCL · GBUniversity of Liverpool · GBUniversity of the Witwatersrand · ZA

Funding

Medical Research Council MC_UU_12023/23
6 · The paper itself

Abstract

Data on immune mediators in the genital tract and the factors that modulate them in sub-Saharan women are limited. Cervicovaginal lavage (CVL) samples from 430 sexually active women from Kenya, South Africa, and Rwanda were analyzed for 12 soluble immune mediators using Bio-Plex and Meso Scale Discovery multiplex platforms, as well as single enzyme-linked immunosorbent assays. Ten bacterial species were quantified in vaginal swab samples. Bacterial vaginosis (BV) was defined by Nugent scoring. CVL samples from HIV-infected women showed a clear-cut proinflammatory profile. Pregnant women, adolescents, and women engaging in traditional vaginal practices differed in specific soluble markers compared to reference groups of adult HIV-negative women. Cervical mucus, cervical ectopy, abnormal vaginal discharge, and having multiple sex partners were each associated with an increase in inflammatory mediators. The levels of interleukin-1α (IL-1α), IL-1β, IL-6, IL-12(p70), and IL-8 were elevated, whereas the IL-1RA/IL-1(α+β) ratio decreased in women with BV. The level of gamma interferon-induced protein 10 was lower in BV-positive than in BV-negative women, suggesting its suppression as a potential immune evasion mechanism by BV-associated bacteria. Lactobacillus crispatus and Lactobacillus vaginalis were associated with decreased proinflammatory cytokines and each BV-associated species with increased proinflammatory cytokines. Remarkably, the in vitro anti-HIV activity of CVL samples from BV-positive women was stronger than that of BV-negative women. In conclusion, we found significant associations of factors, including vaginal microbiota, which can influence immune mediators in the vaginal environment in sexually active women. These factors need to be considered when establishing normative levels or pathogenic cutoffs of biomarkers of inflammation and associated risks in African women.

Indexed as

MicrobiotaAdolescentAdultBiomarkersChemokine CXCL10Cross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHIV-1HIV InfectionsHumansInflammation MediatorsInterleukinsKenyaLactobacillusPregnancyBiomarkersChemokine CXCL10Inflammation MediatorsInterleukins

Identifiers

PMID25761460
PMCPMC4412937
OpenAlexW2163488022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.